FibroGen (FGEN) Stock Price, News & Analysis

Company Overview

FibroGen, Inc., headquartered in San Francisco, California, is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapies for serious unmet medical needs. Since its founding in 1993, the company has built a diversified portfolio encompassing small molecules and biologics that address anemia, fibrotic diseases and oncology.

The company’s lead product, roxadustat, is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to treat anemia in chronic kidney disease. Roxadustat has received regulatory approval in China, Japan and several other markets, and is being developed globally through strategic partnerships with Astellas Pharma and AstraZeneca. In addition to roxadustat, FibroGen is advancing pamrevlumab, a monoclonal antibody in late-stage trials for idiopathic pulmonary fibrosis and other fibrotic disorders, as well as early-stage oncology assets aimed at modifying the tumor microenvironment.

FibroGen operates research and development centers across North America, Europe and Asia, leveraging both in-house expertise and external collaborations to drive clinical progress. The company’s global footprint enables efficient regulatory engagement and commercialization in multiple jurisdictions, from China’s rapidly growing pharmaceutical market to established regulatory regions such as the United States and Europe.

Under the leadership of President and Chief Executive Officer Tom Neff, FibroGen emphasizes rigorous science and strategic partnerships to accelerate its pipeline. The management team combines biotech innovation with industry experience, steering the company through clinical milestones and regulatory approvals while seeking to bring transformative medicines to patients worldwide.

Key Stats

• Today's Range: $9.23 to $9.75
• 50-Day Range: $8.08 to $10.04
• 52-Week Range: $4.85 to $12.60
• Volume: 31,125 shs
• Average Volume: 40,794 shs
• Market Capitalization: $39.57 million
• P/E Ratio: 0.18
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

FibroGen Stock Analysis - MarketRank™

FibroGen scored higher than 5% of companies evaluated by MarketBeat, and ranked 879th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

FibroGen has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

FibroGen has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for FibroGen are expected to grow in the coming year, from ($0.80) to ($0.45) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of FibroGen is 0.18, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.82.

Price to Earnings Ratio vs. Sector

The P/E ratio of FibroGen is 0.18, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.89.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for FGEN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

FibroGen does not currently pay a dividend.

Dividend Growth

FibroGen does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for FGEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, FibroGen insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.07% of the stock of FibroGen is held by insiders.

Percentage Held by Institutions

72.71% of the stock of FibroGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/10/2025
• Today: 10/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:FGEN
• CIK: 921299
• Web: www.fibrogen.com
• Phone: (415) 978-1200
• Fax: 415-978-1902
• Employees: 570
• Year Founded: 1993

Profitability

• EPS (Trailing Twelve Months): $53.48
• Trailing P/E Ratio: 0.18
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$47.58 million
• Net Margins: 2,598.55%
• Pretax Margin: -630.78%
• Return on Equity: N/A
• Return on Assets: -26.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.71
• Quick Ratio: 3.60

Sales & Book Value

• Annual Sales: $29.62 million
• Price / Sales: 1.34
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($50.89) per share
• Price / Book: -0.19

Miscellaneous

• Outstanding Shares: 4,050,000
• Free Float: 3,921,000
• Market Cap: $39.57 million
• Optionable: Optionable
• Beta: 0.77